Cyclo Therapeutics Inc (CYTH) Return on Equity ROE from the third quarter 2024 to third quarter 2023 and annually, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cyclo Therapeutics Inc   (NASDAQ: CYTH)

Cyclo Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cyclo Therapeutics Inc in the third quarter 2024?
Due to the lack of equity, it was not possible to calculate Cyclo Therapeutics Inc 's return on equity (ROE) in its third quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Equity Change - - - 547.61 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -25 -21 -19 -20 -19
Return On Equity (TTM) - - -2741.56 % -4505.67 % -
CYTH's Total Ranking # # # # #
Equity (TTM) in Millions -13 -5 1 5 -1
Seq. Equity Change - - -87.18 % - -
Seq. Net Income Change - - - - -

Back to CYTH Management Effectiveness >> CYTH's 5 Years Annual ROE >> Compare CYTH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





CYTH Annual Return On Equity (Dec 31 2023)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 5 1 16 10 1
Y / Y Equity Change 547.61 % -95.31 % 49.93 % 1016.74 % -5.7 %
Net Income in Millions -20 -20 -15 -14 -9
Y / Y Net Income Change - - - - -
Return On Equity -421.64 % -2730.58 % -98.59 % -136.68 % -955.32 %

Back to CYTH Management Effectiveness >> CYTH's 5 Years Annual ROE >> Compare CYTH ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CYTH's' Return on Equity at Yahoo Finance
CYTH's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CYTH's Competitors
Subscribers only: Roe for Cyclo Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for CYTH's Customers




Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector ROE
Ir med Inc   1,796.27 %
Inhibrx Biosciences Inc   1,450.05 %
Organon and Co   846.18 %
Hca Healthcare Inc   613.42 %
Gridai Technologies Corp  555.42 %
Alaunos Therapeutics Inc   424.57 %
Longduoduo Co Ltd  214.51 %
Keenova Therapeutics Plc  172.76 %
Halozyme Therapeutics Inc   156.40 %

Date modified: 2026-06-22T14:32:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.